Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Nobuyuki Yamamoto(Wakayama Medical University), Takayuki Asato(Takeda (Japan)), Kōichi Goto(National Cancer Center Hospital East), Pingkuan Zhang(Melanoma Institute Australia), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Kentarou Kudou(Takeda (Japan)), Makoto Nishio(Japanese Foundation For Cancer Research), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Masashi Kondo(Fujita Health University), Toru Kumagai(University of Pennsylvania), Toshihide Yokoyama(Kurashiki Central Hospital)
Cited by 6
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k